Exhibit 99.1

 

PRESS RELEASE

Patent Approval for BiondVax:

BiondVax Receives Approval for Patent in Korea for its Universal Flu Vaccine

The patent approval extends and strengthens BiondVax's intellectual property portfolio internationally

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) which is developing the Universal Flu Vaccine, announced today that its main patent on the Multimeric Multi-Epitope Polypeptide Influenza Vaccines family, was granted in Korea.

This is a family of patents for vaccination against influenza in humans, and specifically vaccines that confer long-lasting protection against multiple and differing flu strains. The Korean Intellectual Property Office accepted BiondVax’s claims for M-001 and similar polypeptides. This patent approval strengthens BiondVax's intellectual property in international markets.

Patent protection has already been granted in other countries: the US, Europe, Japan, Hong Kong, Australia, China, Russia and Mexico.

Ron Babecoff, CEO of BiondVax said “Asia has been the site of the start of many recent bird-flu pandemics, including H5N1 and H7N9. Our new patent approval in Korea provides us with an opportunity to establish a strategic partnership in this market. This will enable us to offer local health authorities and governments our pandemic preparedness plan, with the establishment of national stockpiles against all types of influenza pandemics.”

About BiondVax Pharmaceuticals Ltd

BiondVax is an innovative biopharmaceutical company developing a universal flu vaccine, designed to provide multi-season and multi-strain protection against most human influenza virus strains, including both seasonal and pandemic flu strains.

BiondVax’s technology utilizes a unique, proprietary combination of conserved and common peptides from influenza virus proteins to activate both arms of the immune system for a cross-protecting and long-lasting effect.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve certain risks and uncertainties reflect the management's current views with respect to certain current and future events and are subject to various risks, uncertainties and assumptions that could cause the results to differ materially from those expected by the management of BiondVax Pharmaceuticals Ltd. risks and uncertainties include, but are not limited to, the risk that drug development involves a lengthy and expensive process with uncertain outcome, BiondVax’s ability to continue obtaining and maintaining intellectual property protection for our Universal Flu Vaccine, risks inherent in the development and commercialization of potential products, dependence upon collaborators, and adequacy of capital resources for product development and commercialization. The risks, uncertainties and assumptions referred to above are discussed in detail in our reports filed with the Securities and Exchange Commission, including our Prospectus which was declared effective on May 11, 2015. BiondVax Pharmaceuticals Ltd. undertakes no obligation to update or revise any forward-looking statements.

For further information, please contact:

Company Contact Limor Chen, Director of BD limor.c@biondvax.com Investor Relations Contact GK Investor Relations Kenny Green, Partner +1 646 201 9246 kenny@biondvax.com

Weizmann Science Park, 14 Einstein Street, PO Box 4143, Nes Ziona 74140, Israel
Tel: +972 8 930 2529 ● Fax:+972 8 930 2531 ● www.biondvax.com